Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developments and challenges of FLT3 inhibitors in acute myeloid leukemia

14 Sept 2022

Abstract excerpt

FLT3 mutations are one of the most common genetic alterations in acute myeloid leukemia (AML) and are identified in approximately one-third of newly diagnosed patients. Aberrant FLT3 receptor signaling has important implications for the biology and clinical management of AML. In recent years, targeting FLT3 has been a part of every course of treatment in FLT3-ITD/TKD-mutated AML and contributes to substantially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36185253
DOI: 10.3389/fonc.2022.996438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developments and challenges of FLT3 inhibitors in acute myeloid leukemiaPMID 36185253Read ↗

FLT3 inhibitors: clinical potential in acute myeloid leukemiaSemantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Semantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentSemantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

Targeting FLT3 Mutations in Acute Myeloid LeukemiaSemantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.Semantic proximity Read ↗

Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity Read ↗

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.